BACE1 (␤-site amyloid precursor protein-cleaving enzyme-1) is a membrane-bound aspartic protease that cleaves amyloid precursor protein to produce a neurotoxic peptide, amyloid ␤-peptide, and has been implicated in triggering the pathogenesis of Alzheimer disease. We showed previously that BACE1 cleaves ␤-galactoside ␣2,6-sialyltransferase I (ST6Gal I) to initiate its secretion, but it remained unclear how BACE1 affects the cellular level of ␣2,6-sialylation. Here, we found that BACE1 overexpression in Hep3B cells increased the sialylation of soluble secreted glycoproteins, but did not affect cellsurface sialylation. The sialylation of soluble glycoproteins was not increased by ST6Gal I overexpression alone, but was increased by co-overexpression of ST6Gal I and BACE1 or by expression of the soluble form of ST6Gal I, suggesting that soluble ST6Gal I produced by BACE1 plays, at least in part, a role in the sialylation of soluble glycoproteins. We also found that plasma glycoproteins from BACE1-deficient mice exhibited reduced levels of ␣2,6-sialylation compared with those from wild-type mice. We propose a novel regulatory mechanism in which cleavage and secretion of ST6Gal I enhance the sialylation of soluble glycoprotein substrates.
BACE1 (␤-site amyloid precursor protein-cleaving enzyme-1)
is a membrane-bound aspartic protease that cleaves amyloid precursor protein to produce a neurotoxic peptide, amyloid ␤-peptide, and has been implicated in triggering the pathogenesis of Alzheimer disease. We showed previously that BACE1 cleaves ␤-galactoside ␣2,6-sialyltransferase I (ST6Gal I) to initiate its secretion, but it remained unclear how BACE1 affects the cellular level of ␣2,6-sialylation. Here, we found that BACE1 overexpression in Hep3B cells increased the sialylation of soluble secreted glycoproteins, but did not affect cellsurface sialylation. The sialylation of soluble glycoproteins was not increased by ST6Gal I overexpression alone, but was increased by co-overexpression of ST6Gal I and BACE1 or by expression of the soluble form of ST6Gal I, suggesting that soluble ST6Gal I produced by BACE1 plays, at least in part, a role in the sialylation of soluble glycoproteins. We also found that plasma glycoproteins from BACE1-deficient mice exhibited reduced levels of ␣2,6-sialylation compared with those from wild-type mice. We propose a novel regulatory mechanism in which cleavage and secretion of ST6Gal I enhance the sialylation of soluble glycoprotein substrates.
The generation and deposition of the amyloid ␤-peptide in the brain are a hallmark of Alzheimer disease and have been implicated in the pathogenesis of Alzheimer disease (1) . The amyloid ␤-peptide is generated from the membrane-spanning ␤-amyloid precursor protein via sequential proteolytic cleavage by ␤-and ␥-secretases. BACE1 (␤-site amyloid precursor protein-cleaving enzyme-1), a type I membrane-bound aspartic protease, has recently been identified as ␤-secretase (2-5).
Other substrates for BACE1 have been reported, including ␤-galactoside ␣2,6-sialyltransferase I (ST6Gal I) 3 (6 -8) , the adhesion protein P-selectin glycoprotein ligand-1 (9), the ␤-subunit of voltage-gated sodium channels (10) , ␤-amyloid precursor protein-like proteins (11) , and low density lipoprotein receptor-related protein (12) . BACE1 has been identified as the sole ␤-secretase because no measurable amyloid ␤-peptide is synthesized in BACE1-deficient mice (13, 14) . Previous reports have revealed that BACE1-deficient mice show subtle neuronal abnormalities (15) (16) (17) . Furthermore, BACE1 was shown recently to be required for the processing of neuregulin-1, and BACE1-deficient mice display hypomyelination (18) .
BACE1 is highly expressed in neurons, but its ubiquitous expression at lower levels has also been demonstrated (2) . We showed previously that hepatic BACE1 is a major protease for secretion of ST6Gal I into the plasma (8) . Similar to the case for ST6Gal I, some Golgi-localized glycosyltransferases are cleaved by proteases and subsequently secreted by cells. Indeed, many glycosyltransferases have been found in body fluids such as serum, colostrum, and milk (19 -22) . Furthermore, such proteolytic cleavage and secretion into body fluids are affected by various pathological conditions, including malignant transformation and inflammation. Nevertheless, the biological significance of soluble glycosyltransferases has remained unclear (23) because the donor substrates (nucleotide sugars) are not available in body fluids.
To examine how BACE1 overexpression affects cellular sialylation following ST6Gal I cleavage and secretion, we used several experimental systems. First, we utilized Hep3B hepatoma cells in which BACE1 was overexpressed or its expression was reduced by BACE1 small interfering RNAs (siRNAs) and quantified the ␣2,6-sialylation of both secreted and cell-surface gly-coproteins. Next, we used a hepatitis rat model, the Long-Evans Cinnamon (LEC) rat, in which increased BACE1 expression has been confirmed (8) . The LEC rat, a model of Wilson disease, has a deletion in the copper-transporting ATPase gene (ATP7B) (24 -26) . Golgi-localized ATP7B is involved in copper secretion into the plasma, which is coupled with ceruloplasmin synthesis and biliary copper excretion (27) . Similar to patients with Wilson disease, LEC rats suffer from toxic accumulation of copper in the liver, leading to the development of hepatitis and eventually hepatocellular carcinoma (28) . Our previous study using LEC rats revealed that the hepatic BACE1 mRNA level is increased before the hepatitis stage and that plasma ST6Gal I increases at the same time (8) , thereby suggesting a relationship between altered BACE1 expression and the level of sialylation in vivo. We also analyzed the sialylation of plasma glycoproteins from BACE1-deficient mice.
EXPERIMENTAL PROCEDURES
Materials-Male LEC and Wistar rats were purchased from Charles River Laboratories Japan Inc. (Yokohama, Japan) and the Shizuoka Agricultural Cooperative Association for Laboratory Animals (Shizuoka, Japan), respectively, and maintained under specific pathogen-free conditions. Samples from control Long-Evans Agouti (LEA) rats were kindly provided by Dr. Noriyuki Kasai (Tohoku University, Sendai, Japan). BACE1 knock-out mice and their controls (Amgen, Thousand Oaks, CA) were maintained at Charles River Laboratories, Inc. (Wilmington, MA). The sources of the materials used in this study were as follows: tissue culture media and reagents, including RPMI 1640 medium, from Invitrogen; protein molecular mass standards from Bio-Rad; Sambucus sieboldiana agglutinin (SSA)-biotin and SSA-fluorescein isothiocyanate (FITC) from Seikagaku Corp. (Tokyo, Japan); and all other chemicals from Sigma or Wako Chemicals (Tokyo). Protein concentrations were determined using BCA protein assay reagents (Pierce). The commercially available antibodies used were as follows: rabbit anti-BACE1 polyclonal (Abcam, Cambridge, UK), mouse anti-transferrin monoclonal (Nippon BioTest Laboratories Inc., Tokyo), goat anti-transferrin polyclonal (ICN Pharmaceuticals, Inc., Irvine, CA), mouse anti-adaptin-␥ monoclonal (BD Transduction Laboratories), and mouse antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal (Chemicon International, Temecula, CA). Anti-ST6Gal I polyclonal antibody E41 (Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan) was used to detect soluble ST6Gal I starting at Glu 41 in media. pcDNA-BACE1(D93A)-Myc was generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Primer 1 (5Ј-CTCAACATCCTGG-TGGCAACAGGCAACAGGCAGCAGTAAC-3Ј) and primer 2 (5Ј-GTTACTGCTGCCTGTTGCCACCAGGATGTTGAG-3Ј) were used to mutate the catalytic Asp 93 of BACE1 to Ala. Soluble pSVL-ST6Gal I was constructed by inserting a canine insulin signal sequence-ST6Gal I E41 form-FLAG domain fragment, which was generated by PCR and blunted, into the SmaI site of the pSVL vector (29) .
siRNA Transfection-Hep3B cells were plated on 100-mm tissue culture dishes and grown in RPMI 1640 medium containing 10% fetal bovine serum until they reached 30% confluence.
The cells were then transfected with 100 pmol of human BACE1 siRNAs or a control siRNA (AllStars negative control siRNA, Qiagen Inc., Valencia, CA) using 25 l of Lipofectamine 2000 (Invitrogen) in 1.5 ml of Opti-MEM I. The siRNA duplexes targeted to human BACE1 were as follows: siRNA1, 5Ј-AGAUCCUGUCCAUUGAUCUCCACCC-3Ј and 5Ј-GGGUGGAGAUCAAUGGACAGGAUCU-3Ј; and siRNA2, 5Ј-AAGCTTTGTGGAGATGGTGGA-3Ј and 5Ј-TCCACCA-TCTCCACAAAGCTT-3Ј. After 12 h, the medium was exchanged for fresh medium to remove the siRNA duplexes. At 48 h after transfection, the cells were incubated in serum-free Opti-MEM I containing Complete protease inhibitor mixture (Roche Diagnostics) for 12 h. The cells and media were collected for further analysis.
Quantitative Real-time PCR-Total RNA was isolated from Hep3B cells using Sepasol reagent (Nacalai Tesque, Inc., Kyoto, Japan), and 5 g of the isolated RNA was reverse-transcribed with random hexamers using a SuperScript III reverse transcriptase kit (Invitrogen) according to the manufacturer's protocol. For BACE1 and GAPDH primers and probes, we used Assays-on-Demand gene expression products, and the cDNAs were added to TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), which contained all of the reagents for PCR. The probes for BACE1 were labeled with the reporter fluorescent dye FAM TM . The cDNAs were amplified by one cycle at 50°C for 2 min, one cycle at 95°C for 10 min, and 40 cycles at 95°C for 15 s and 50°C for 1 min in a total volume of 20 l using an ABI PRISM 7900HT sequence detection system (Applied Biosystems). The probes for GAPDH were labeled with VIC at their 5Ј-ends and the quencher dye TAMRA TM at their 3Ј-ends. The expression levels of the target genes were measured in duplicate and normalized to the corresponding GAPDH expression levels.
Western Blot Analysis-We examined the levels of transferrin in media from Hep3B cells or rat plasma by Western blot analysis. We also analyzed the levels of intracellular ST6Gal I in Hep3B cell lysates, which were prepared using T-PER buffer (Pierce) containing a protease inhibitor mixture. Cell lysates, plasma, and proteins precipitated from media with acetone were treated with Laemmli sample buffer (30), separated by SDS-PAGE (5-20% gradient gel), and transferred to a nitrocellulose membrane. The membrane was incubated with anti-transferrin antibody (1:1000 dilution) or anti-ST6Gal I antibody E41 (1:100 dilution), followed by horseradish peroxidase-conjugated antirabbit goat or mouse IgG (1:1000 dilution; GE Healthcare) as the secondary antibody. A chemiluminescent substrate (Pierce) was used for detection of the bound antibodies (6) . For depletion of transferrin, the media (0.2 ml) of Hep3B cells were treated with anti-transferrin antibody (5 l) and protein G-agarose (20 l). After the resin was washed with phosphate-buffered saline (PBS), the original media and unbound and protein G-agarose-bound fractions were used for further analysis. After detection of intracellular ST6Gal I in the Hep3B cell lysates, the membrane was washed with Restore Western blot stripping buffer (Pierce) and incubated with anti-GAPDH antibody. All signals were quantified with a LuminoImage LAS-1000plus analyzer (Fuji, Tokyo).
SSA Lectin Blot Analysis-Hep3B cells grown in RPM I 1640 medium containing 10% fetal bovine serum were washed with serum-free Opti-MEM I containing EDTA-free Complete protease inhibitor mixture for 12 h. Aliquots (200 l) of the media were then precipitated with 300 l of ice-cold acetone. Rat plasma samples (10 g of protein) or concentrated media derived from Hep3B cells were treated with Laemmli sample buffer, separated by SDS-PAGE (5-20% gradient gel), and transferred to a polyvinylidene difluoride membrane (Atto Co., Ltd., Tokyo). The membrane was blocked with 1% bovine serum albumin in PBS for 2 h and incubated with SSA-biotin (1:100 dilution in 1% bovine serum albumin-containing PBS). After three washes with PBS containing 0.05% Tween 20 (PBS/ Tween), the membrane was incubated with horseradish peroxidase-labeled streptavidin (1:1000 dilution in 1% bovine serum albumin-containing PBS; Sigma), and the signals were quantified with the LuminoImage analyzer.
Isoelectric Focusing-Aliquots (0.5 ml) of media from Hep3B cells grown in Opti-MEM I for 48 h were concentrated and desalted by centrifugation on a Nanosep device (Pall Corp., Ann Arbor, MI). Isoelectric focusing was performed on an Ampholine PAGplate (pH 4.5-6.0; GE Healthcare) to analyze the level of sialylation of transferrin. After electrophoresis, the proteins were transferred to a nitrocellulose membrane and analyzed by immunostaining with anti-transferrin antibody. Standard transferrin and asialotransferrin were prepared by mild acid hydrolysis (25 mM HCl, 80°C, 1 h) of transferrin and subjected to Coomassie Blue staining (PhastGel Blue R, GE Healthcare).
SSA Lectin Enzyme-linked Immunosorbent Assay-Each well of a 96-well plate (Nalge Nunc International, Naperville, IL) was incubated overnight at 4°C with a plasma sample (1:40,000 dilution or a series of serial dilutions with PBS) or serial dilutions of ␣ 1 -acid glycoprotein (up to 6 g/well) as the standard. After five washes with PBS/Tween, the wells were incubated with 25% Block Ace (Dai Nihon Seiyaku Co., Osaka, Japan) in PBS at 25°C for 2 h. After washing with PBS/Tween, the wells were sequentially incubated with SSA-biotin (1:1000 dilution in 12.5% Block Ace-containing PBS/Tween) and horseradish peroxidase-conjugated streptavidin (1:1000 dilution in 12.5% Block Ace-containing PBS/Tween) at 25°C for 1 h each. After extensive washing with PBS/Tween, the wells were incubated with SureBlue TMB microwell peroxidase substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). The reaction was terminated by the addition of 1 N HCl. One unit is defined as the amount of SSA epitopes in 1 g of ␣ 1 -acid glycoprotein detected by the assay system.
Immunofluorescence Staining-Hep3B cells transfected with rat pcDNA-ST6Gal I were grown for 48 h at 33°C on poly-Llysine-coated chamber slides (Nalge Nunc International). After fixation with ice-cold methanol for 15 min at Ϫ20°C, the cells were incubated with anti-ST6Gal I antibody E41 (1:40 dilution) and anti-adaptin-␥ antibody (1:50 dilution). After blocking with 5% goat serum in PBS, the cells were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG (1:100 dilution) and Alexa Fluor 546-conjugated anti-mouse IgG (1:100 dilution), respectively. After washing with PBS, the samples were mounted in ProLong Gold antifade reagent containing 4Ј,6-diamidino-2-phenylindole (Invitrogen) and observed using an Axiovert 100M inverted microscope (LSM510, Carl Zeiss AG, Jena, Germany) equipped with a C-Apochromat (ϫ63, 1.4 numerical aperture) oil immersion objective. Appropriate excitation and barrier filters were used to observe the fluorescence.
Flow Cytometry-Hep3B cells were transfected with pcDNA-BACE1, pcDNA-BACE1(D93A), or the empty vector and grown on 100-mm tissue culture plates for 24 h. Next, the cells were detached with 5 mM EDTA in PBS and resuspended as single cell suspensions in fluorescence-activated cell sorter buffer (PBS containing 1% bovine serum albumin and 0.05% sodium azide) at 1 ϫ 10 7 cells/ml. Cells (5 ϫ 10
5
) were incubated with SSA-FITC (10 g/ml) for 30 min on ice, washed three times, and suspended in fluorescence-activated cell sorter buffer. Flow cytometry data were acquired using an EPICS XL cytometer (Beckman Coulter, Inc., Fullerton, CA) and analyzed using EXPO32 software (Beckman Coulter, Inc.).
RESULTS

BACE1 Expression
Enhances the ␣2,6-Sialylation of Soluble Secreted Proteins-We showed previously that BACE1 cleaves ST6Gal I to initiate its secretion using the following experimental systems: (i) COS or human embryonic kidney 293 cells in culture, (ii) BACE1-deficient and BACE1 transgenic mice, and (iii) in vitro incubations of purified BACE1 with ST6Gal I (6, 8, 31) . However, it has remained unclear how cellular sialylation is affected by such ST6Gal I cleavage. ST6Gal I is highly expressed in the liver (32) , and a significant amount of hepatic ST6Gal I is cleaved and secreted into the plasma, particularly by the socalled acute-phase reaction (19, 33) . 4 Therefore, we examined how BACE1 overexpression affects the sialylation of soluble glycoproteins and/or cell-surface glycoproteins in Hep3B hepatoma cells. After Hep3B cells were cultured in serum-free media, proteins secreted into the media fractions were concentrated and analyzed by blotting with SSA lectin, which recognizes Sia␣2,6Gal epitopes. Even though 20 sialyltransferase genes have been identified to date, ST6Gal I is likely to be the sole enzyme that catalyzes the synthesis of Sia␣2,6Gal structures in the liver. SSA-reactive signals were observed in the 60-, 70-, and 80-kDa regions on the blot for conditioned media from Hep3B cells (Fig. 1A) . Hep3B cells were reported to secrete transferrin (ϳ80 kDa) into the culture media. In fact, we were able to deplete the 80-kDa signal using anti-transferrin antibody, indicating that the SSA-reactive signal at 80 kDa was derived from transferrin (Fig. 1B) . The other signals appeared to be mixtures of ␣ 1 -chymotrypsin, ␣ 1 -antitrypsin, and fibrinogen ␥-chain based on the available proteomic information (au.expasy.org/). Following BACE1 overexpression, most of the SSA-reactive signal intensities were increased by ϳ1.4-fold compared with control experiments. In contrast, expression of the catalytically inactive mutant BACE1(D93A) rather decreased the signal intensities. These results suggest that the proteolytic activity of BACE1 is required for the increase in SSA-reactive epitopes in the media. Next, we examined whether the levels of the core protein portion of transferrin are increased by BACE1 expression. Following BACE1 expression, there were no significant changes in the level of transferrin itself in terms of the mRNA and protein levels (Fig. 1A and supplemental Fig. 1 ), but the SSA-reactive 80-kDa signal was significantly increased. Because Lawrence et al. (34) showed previously that the glycosylation sites of transferrin are not involved in transferrin-transferrin receptor interactions, sialylation of transferrin would not affect the endocytosis of transferrin via the transferrin receptor. To obtain direct evidence that the sialylation of transferrin is increased by BACE1 expression, we performed isoelectric focusing. After BACE1 overexpression, transferrin containing more negative charges was significantly increased (Fig. 1C) . Our previous study revealed that BACE1 overexpression induces slight changes in cellular ␣2,6-sialylation in human embryonic kidney cells (6) . We also performed similar experiments using other cell lines, such as COS and Chinese hamster ovary, but did not find any changes in their levels of sialylation (data not shown). Following BACE1 overexpression, we clarified that the amount of ST6Gal I mRNA remained unchanged in Hep3B cells (supplemental Fig. 1 ). Taken together, these results suggest that the effects of BACE1 overexpression are cell type-specific, i.e. the secretion machinery is highly developed in hepatic lineage cells to secrete plasma glycoproteins.
We further investigated whether inhibition of BACE1 expression would have the opposite effect on the sialylation of soluble secreted proteins in Hep3B cell media. To achieve this, we used two kinds of BACE1 siRNA duplexes as well as a nonsilencing siRNA duplex as a negative control. First, we confirmed that BACE1 siRNA1 and siRNA2 actually knocked down BACE1 expression with efficiencies of 23 and 24%, respectively ( Fig. 2A) . Next, we sought to determine whether the BACE1 siRNAs also affect the sialylation of transferrin secreted by Hep3B cells. Sialylation of transferrin was found to be reduced to 60 and 54% in siRNA1-and siRNA2-treated cells, respectively (Fig. 2B) . Concomitantly, the amounts of SSA epitopes on the glycoproteins secreted by Hep3B cells were reduced by the siRNA treatments (data not shown). The possibilities that the levels of ST6Gal I and transferrin mRNAs may be changed by knockdown of BACE1 expression were ruled out by real-time PCR analysis (supplemental Fig. 2 ). Taken together, these results indicate that the ␣2,6-sialylation of soluble glycoproteins is reduced by inhibition of BACE1 expression in Hep3B cells.
Next, we examined whether BACE1 expression also affects the sialylation of cell-surface glycoproteins. To achieve this, Hep3B cells expressing BACE1 or BACE1(D93A) or control were precipitated with cold acetone and subjected to SSA lectin blot analysis (upper blot). Aliquots (5 l) of the media were subjected to immunoblot analysis with anti-transferrin (anti-Tf) antibody (lower blot). All of the SSA signals (right graph) and the transferrin signals at ϳ80 kDa (left graph) were quantified using the LuminoImage LAS-1000plus analyzer and normalized to the corresponding control signals. In the case of the SSA epitopes on transferrin, each signal intensity at ϳ80 kDa was divided by the intensity of the corresponding transferrin signal detected with anti-transferrin antibody. All data are presented as the means Ϯ S.E. (n ϭ 5). *, p Ͻ 0.05; **, p Ͻ 0.001. B, Hep3B cells were incubated in serum-free media for 12 h in the presence of protease inhibitors. The media (0.2 ml) were collected and incubated with protein G-agarose in the presence or absence of anti-transferrin antibody. The original media sample, protein G-agarose-bound fraction (Ppt), and unbound fraction (Sup) were analyzed by SSA lectin staining or immunoblotting with anti-transferrin antibody. C, Hep3B cells were transfected with pcDNA-BACE1 or the empty vector and then incubated in serum-free media for 48 h. The media (1 ml) were desalted and concentrated before the proteins in the media were analyzed by isoelectric focusing. After electrophoresis, the proteins were transferred to a nitrocellulose membrane and analyzed by immunostaining with anti-transferrin antibody. Standard transferrin (Tf) and asialotransferrin (AsTf) were visualized by Coomassie Brilliant Blue staining. FIGURE 2. Effects of BACE1 siRNAs on ␣2,6-sialylated glycoproteins secreted by Hep3B cells. Hep3B cells were transfected with siRNA duplexes for BACE1 or a control siRNA. At 48 h after transfection, the media were exchanged for serum-free media. After 12 h of culture, the cells and media were collected for RNA analysis and SSA lectin blot analysis, respectively. A, the amounts of BACE1 and GAPDH mRNAs were analyzed by real-time PCR using a standard curve method. All values were normalized to the corresponding level of GAPDH mRNA. Data are presented as the means Ϯ S.E. of three independent experiments (n ϭ 3). B, the proteins in the media (0.1 ml) were precipitated by cold acetone and analyzed by SSA lectin blot analysis. Each signal intensity at 80 kDa was divided by the corresponding intensity of the transferrin (Tf) signal. Data are presented as the means Ϯ S.E. of three independent experiments (n ϭ 3). **, p Ͻ 0.01. cells were stained with SSA-FITC, and the cell-surface SSA epitopes were measured by flow cytometry. There were no changes in the levels of surface ␣2,6-sialylation (Fig. 3) . Furthermore, knockdown of BACE1 expression did not alter the level of cell-surface ␣2,6-sialylation in Hep3B cells (supplemental Fig. 3 ). We assume that the reason why changes in the level of ST6Gal I expression did not alter the ␣2,6-sialylation of cell-surface glycoproteins could be that the level of endogenous ST6Gal I is sufficiently high to saturate the cell-surface ␣2,6-sialylation (35) . Taken together, these results indicate that BACE1 expression selectively enhances the ␣2,6-sialylation of soluble glycoproteins.
Expression of Soluble ST6Gal I Enhances the Sialylation of Soluble Glycoproteins-Because we showed previously that ST6Gal I is cleaved by BACE1 (6 -8), we hypothesized that the production of soluble ST6Gal I would be involved in the increased ␣2,6-sialylation of soluble glycoproteins. When intact ST6Gal I was overexpressed in Hep3B cells, the ␣2,6-sialylation of secreted transferrin and total soluble glycoproteins remained unchanged compared with that in control cells (Fig. 4A) . Next, we overexpressed ST6Gal I together with BACE1, expecting that soluble ST6Gal I would be produced by BACE1. Indeed, the cotransfection enhanced the ␣2,6-sialylation of soluble glycoproteins by ϳ1.4-fold. To confirm the involvement of soluble ST6Gal I in the enhanced ␣2,6-sialylation, we prepared a soluble ST6Gal I chimeric protein in which a luminal part of ST6Gal I was combined with an insulin signal peptide. This exogenous soluble ST6Gal I successfully increased the ␣2,6-sialylation of soluble glycoproteins. Next, we checked whether exogenous soluble ST6Gal I would also increase the ␣2,6-sialylation of membrane-bound glycoproteins. As shown in Fig. 4B , neither soluble ST6Gal I nor intact ST6Gal I overexpression affected the level of ␣2,6-sialylation of cell-surface glycoproteins. Taken together, these results suggest that increases in soluble ST6Gal I, but not membrane-bound ST6Gal I, are responsible for the enhanced ␣2,6-sialylation of soluble glycoproteins in Hep3B cells.
Membrane-bound ST6Gal I is cleaved and subsequently secreted by the cell. Extracellular ST6Gal I is unlikely to show any enzyme activity because the sugar donor substrate CMPSia is not available outside of the cell. We therefore speculated that soluble ST6Gal I would function within the cell just before its secretion. On the basis of our previous study in which ST6Gal I and BACE1 were co-localized in the Golgi apparatus (6), we speculated that soluble ST6Gal I would be observed near the Golgi apparatus. To examine the presence of intracellular soluble ST6Gal I, we used an antibody that specifically recognizes the soluble form of rat ST6Gal I starting at Glu 41 (the BACE1 product) (6, 7) . In Hep3B cells overexpressing rat ST6Gal I, soluble rat ST6Gal I was indeed localized around the perinuclear area and partially co-localized with adaptin-␥ in the trans-Golgi, indicating that a certain fraction of soluble ST6Gal I was present inside the cells (Fig. 5A) . Biochemical analysis further revealed that soluble ST6Gal I was detectable in Hep3B cell lysates, even after extensive washing of the cells, again suggesting the presence of soluble ST6Gal I inside the cells (Fig.   FIGURE 3 . Effects of BACE1 expression on cell-surface ␣2,6-sialylated glycoproteins. Hep3B cells were transfected with pcDNA-BACE1, pcDNA-BACE1(D93A), or the empty vector. After transfection, the cells were cultured for 24 h and then stained with SSA-FITC for flow cytometry analysis. 5B). Furthermore, intracellular soluble ST6Gal I was increased by BACE1 overexpression in Hep3B cells. Finally, the level of intracellular soluble ST6Gal I was increased when the cells were grown at 33°C, possibly because of the accumulation of newly synthesized soluble ST6Gal I in secretory vesicles.
BACE1 Expression Is Correlated with the Level of Sialylation of Plasma Proteins in
Vivo-Next, we examined whether increased BACE1 expression could enhance the ␣2,6-sialylation of glycoproteins in vivo. First, we used LEC rats, an animal model that spontaneously accumulates copper in the liver and incurs hepatic damage. We reported previously that the hepatic BACE1 mRNA level in LEC rats at 8 weeks of age is ϳ3.5-fold higher than the corresponding level at 4 weeks of age, whereas the hepatic ST6Gal I mRNA level remains unchanged, and that the level of plasma ST6Gal I increases along with hepatic BACE1 expression (8) . SSA lectin blot analysis of plasma glycoproteins revealed that most of the SSA-reactive signals in LEC rats were significantly higher at 8 weeks of age than at 4 weeks of age (Fig. 6A) . Control LEA rats did not show any increases in the SSA-reactive signals during the same period. Even though the 80-kDa SSA signal, which is possibly transferrin, was markedly increased at 8 weeks of age, the level of transferrin protein itself remained unchanged. Coomassie Brilliant Blue gel staining of the same plasma samples revealed that some of the proteins were slightly increased in LEC rats at 8 weeks of age (Fig. 6B) . Nevertheless, these findings did not seem to fully explain the dramatically increased intensities of the SSA signals.
Next, we examined the plasma levels of ␣2,6-sialylated glycoproteins in BACE1-deficient mice. To achieve this, we used our recently developed SSA lectin enzyme-linked immunosorbent assay system, by which the plasma levels of ␣2,6-sialylated FIGURE 5 . Effects of BACE1 expression on intracellular ST6Gal I. A, Hep3B cells were transfected with rat pcDNA-ST6Gal I and incubated for an additional 24 h. The cells were then fixed with ice-cold methanol and incubated with anti-ST6Gal I antibody E41 plus anti-adaptin-␥ antibody, followed by Alexa Fluor 488-conjugated anti-rabbit IgG and Alexa Fluor 546-conjugated anti-mouse IgG, respectively. DAPI, 4Ј,6-diamidino-2-phenylindole. B, Hep3B cells were transfected with rat pCAGGS-ST6Gal I together with BACE1 or the empty vector (Cont.) and then incubated at 37 or 33°C. At 24 h after transfection, cell lysates (30 g of protein) were prepared for immunoblot analysis using anti-ST6Gal I antibody E41 (for the soluble rat ST6Gal I E41 form) or anti-GAPDH antibody. FIGURE 6. SSA lectin blotting of plasma proteins from LEC rats and control LEA rats. A, plasma samples (30 g of protein) from male LEC and LEA rats at 4 (4wks) and 8 (8wks) weeks of age (n ϭ 3 for each) were analyzed by SSA lectin blotting (upper panel). The levels of transferrin (Tf) in plasma samples (0.2 g of protein) from male LEC rats at 4 and 8 weeks of age (n ϭ 3 for each) were analyzed by immunostaining with anti-transferrin antibody (lower panel). B, plasma samples (10 g of protein) from LEC and LEA rats at 4 and 8 weeks of age (n ϭ 3 for each) were separated by SDS-PAGE and stained with Coomassie Brilliant Blue.
glycoproteins can be accurately quantified. Plasma from ST6Gal I-deficient mice did not give any significant signals in this assay (Fig. 7, left panel) , confirming that the assay is specific for ST6Gal I products. In this assay, plasma volumes of up to 0.05 l were in the linear range. Using this system, we quantified the amount of SSA epitopes in the plasma of BACE1-deficient mice. BACE1-deficient mice had only ϳ76% of the number of SSA epitopes in their plasma compared with the number in control mice (p Ͻ 0.01) (Fig. 7, right panel) , indicating that BACE1 enhances the ␣2,6-sialylation of plasma proteins in vivo.
DISCUSSION
We showed previously that BACE1 cleaves ST6Gal I to initiate its secretion process (6 -8) . In this study, we have demonstrated that BACE1 affects the ␣2,6-sialylation of proteins secreted from Hep3B cells. Following BACE1 overexpression in Hep3B cells, the ␣2,6-sialylation of soluble secreted glycoproteins was significantly increased, whereas that of cell-surface glycoproteins remained unchanged. We have also demonstrated that BACE1-deficient mice exhibit reduced levels of ␣2,6-sialylation of plasma glycoproteins. The catalytically inactive BACE1 mutant did not enhance the sialylation, indicating that BACE1-dependent cleavage of physiological substrates, possibly ST6Gal I, is required for the enhanced sialylation. As shown in Fig. 8 , we assumed that soluble ST6Gal I, being free from physiological hindrance because of the loss of its membrane anchor region, would efficiently catalyze the sialylation of soluble glycoproteins in the Golgi, trans-Golgi network, or secretory vesicles. This assumption is supported by our finding that an exogenous soluble ST6Gal I chimeric protein consisting of an insulin signal peptide and a luminal part of ST6Gal I also enhanced the sialylation of soluble glycoproteins, whereas intact ST6Gal I did not. Using an antibody specific for the newly generated N terminus of soluble ST6Gal I, we succeeded in observing its localization in the intracellular region.
As a result of the acute-phase reaction, a large quantity of glycoproteins is synthesized in the liver and subsequently secreted into the plasma. This process is part of the self-defense mechanism against tissue damage from trauma, infection, or a tumor burden (36) . Most plasma glycoproteins are sialylated by hepatic ST6Gal I, and the presence of Sia residues is a "tag" for circulation in the bloodstream. Indeed, the non-sialylated forms of glycoproteins, asialoglycoproteins, are taken up by hepatocytes, and this process is mediated by asialoglycoprotein receptors (37) . During the acute-phase reaction, hepatic ST6Gal I and plasma ST6Gal I are both up-regulated. These increases would be related to the sialylation of plasma glycoproteins and subsequently protect these plasma proteins from clearance by the hepatic asialoglycoprotein receptors. Our previous study using LEC rats, which spontaneously suffer from hepatitis, revealed that hepatic BACE1 expression, but not ST6Gal I expression, is increased before the hepatitis stage (8) . Here, we found that the sialylation of plasma glycoproteins was significantly increased in LEC rats at the same age.
The biological significance of soluble glycosyltransferases in body fluid has been a mystery for many years. Our current findings suggest the importance of soluble ST6Gal I for the ␣2,6-sialylation of soluble glycoproteins. Therefore, soluble ST6Gal I in plasma could be a good biomarker for certain hepatopathological situations (8) . We are currently studying the relationships between plasma ST6Gal I levels and various hepatopathological animal models.
